CATALYSTQuantisnow • 1h ago
SEC Form 4 filed by Rallybio CorporationQuantisnow report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
Why RLYB Stock advanced +0.84% Today — RQD Quant Desk Flash
$15.54 +0.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $15.53
Rallybio Corporation (RLYB) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $83.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RLYB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RLYB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Rallybio Corporation (NASDAQ: RLYB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $15.54 (+0.84% 1D, market cap $83.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RLYB ranks #615 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RLYB compare to CRBP and RANI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLYB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRBP (Corbus Pharmaceuticals Holdings Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $81.6M) and RANI (Rani Therapeutics Holdings Inc. (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $84.4M). Among the 5-stock peer group, RLYB leads on earnings multiple (N/A) while RLYB leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RLYB?
▼
Per RLYB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739410), Rallybio Corporation generated $858.0K in revenue (+34.9% YoY), -$9.0M in net income, and -$29.8M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $15.53 (-0.04%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RLYB)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY RLYB SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (35% of score)
FRED Regime × Technicals: 85% of 52W Range • RSI-14 at 40.4 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 4.13 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$16.79-2.6% Next Q
45
Q2 (-2Q)Grade D$16.35+1.8% Next Q
42
Q3 (-1Q)Grade D$16.65-6.7% Next Q
40
CurrentGrade D-$15.54-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RLYB Turnaround Squeeze
While RLYB currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.71) and Max Pain ($16.32) forces dealer call-delta covering toward $18.45.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RLYB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RLYB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RLYB Stock advanced +0.84% Today — RQD Quant Desk Flash
Rallybio Corporation (RLYB) advanced +0.84% to $15.54, trading at 85% of its 52-week range ($3.67 – $17.57). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 85% of its 52-week range ($3.67 – $17.57) with RSI-14 at 40.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.7% around $15.54 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RLYB Headlines & Catalysts
CATALYSTStock Titan • 4h ago
To cover vesting taxes, Rallybio (RLYB) CFO sells 599 shares at $16.04.Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
CATALYSTBusiness Wire • 7h ago
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBBusiness Wire report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 10h ago
RLYB: A $50.0M termination fee drove 9M profit as the Avenzo merger advancedTradingView report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com South Africa • 13h ago
Form 4 Rallybio Corp: Christine A. Nash (Director) For: 28 October By Investing.comInvesting.com South Africa report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
CATALYSTStock Titan • 16h ago
Rallybio Corp SEC Filing (Oct 16, 2026)Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 19h ago
Rallybio (RLYB) Edges Up 0.35% to $16.99, Sitting Midway Between Key Support and Resistance - Volume Profilehttps://www.siam.in/ report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
CATALYSTStock Titan • 22h ago
A November 4 stockholder vote stands between Rallybio (RLYB) holders and a special cash payout.Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 6d ago
Rallybio Q3 EPS $(0.48) Misses $(0.21) EstimateRallybio (NASDAQ:RLYB) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.21) by 128.57 percent. This is a 57.14 percent increase over losses of $(1.12) per share from the
CATALYSTBenzinga • 7d ago
Rallybio Declares $82.7M Special Cash Distribution To Stockholders And Pre-Funded Warrant Holders, Estimated At $13.56/Share, In Connection With Avenzo Therapeutics MergerAs previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") with
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RLYB)
- ✓Walkthrough of RLYB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RLYB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.06%🛡️ HOLDING TREND SUPPORT
2026-11-02O $15.91H $16.23L $15.54C $15.54VOL 40.1K
RES: $17.16SUP: $15.27SMA50: $16.71SMA200: $12.98
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RLYB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +34.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RLYB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RLYB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RLYB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RLYB)
Health Care Rank #615 of 1016
⚔️ CRBP vs RLYB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RLYB vs. CRBP, RANI, INO, QUCY)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Rallybio Corporation (RLYB) ranks #615 by composite RQD confidence (37/100, grade D-) and #683 by equity capitalization ($83.0M). Within this direct 5-issuer industry benchmark cohort, RLYB leads on earnings valuation at N/A trailing P/E, while RLYB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CRBP currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with RLYB at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RLYB
ACTIVE
Rallybio Corporation | D- | 37/100 | — | — | -35.0% | +0.84% | $83.0M | Benchmark Subject |
| CRBP Corbus Pharmaceuticals Holdings Inc. | D | 47/100 | — | — | -35.0% | 0.00% | $81.6M | /crbp-vs-rlyb → |
| RANI Rani Therapeutics Holdings Inc. (Class A) | D- | 36/100 | — | — | -35.0% | -2.54% | $84.4M | /rani-vs-rlyb → |
| INO Inovio Pharmaceuticals Inc. | E | 34/100 | — | — | -35.0% | -21.95% | $79.8M | /ino-vs-rlyb → |
| QUCY Quantum Cyber N.V. | D- | 35/100 | — | 72.6% | -35.0% | -7.69% | $79.4M | /qucy-vs-rlyb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001739410In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rallybio Corporation (RLYB) reported GAAP revenue of $858.0K (+34.9% vs. FY2024 revenue of $636.0K ) , GAAP net income of -$9.0M, operating cash flow of -$29.8M, and free cash flow of -$29.8M (+39.5% YoY). On the balance sheet, RLYB closed FY2025 with $62.3M in total assets against $0 in total debt (Altman Z-Score: 4.13, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $858.0K | -$9.0M | -$29.8M | -$29.8M | $62.3M | — |
| FY2024 (FY) | 2024-12-31 | $636.0K | -$57.8M | -$49.3M | -$49.3M | $68.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$74.6M | -$60.3M | -$60.3M | — | — |
3. RLYB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RLYB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Rallybio Corporation (NASDAQ: RLYB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $15.54 (+0.84% 1D, market cap $83.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RLYB ranks #615 in composite RQD confidence.
How does RLYB compare to CRBP and RANI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLYB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRBP (Corbus Pharmaceuticals Holdings Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $81.6M) and RANI (Rani Therapeutics Holdings Inc. (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $84.4M). Among the 5-stock peer group, RLYB leads on earnings multiple (N/A) while RLYB leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RLYB?
Per RLYB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739410), Rallybio Corporation generated $858.0K in revenue (+34.9% YoY), -$9.0M in net income, and -$29.8M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RLYB trading relative to its 50-day, 200-day, and 52-week technical levels?
RLYB last traded at $15.54 (+0.84% on volume of 61,724 shares), positioning the stock -7.00% below its 50-day simple moving average ($16.71) and +19.72% above its 200-day simple moving average ($12.98). Across its 52-week range of $3.67 to $17.57, RLYB sits at the 85.4% percentile with a 14-day RSI of 40.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($14.65 to $16.43).
RLYB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RLYB stock moving today?
Why RLYB Stock advanced +0.84% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
RLYB — Rallybio Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:44:51Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD Score is 37, graded D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). The five pillars are:
- Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, the core issue is that the company is not generating cash returns on capital; any upside thesis must rest on future events rather than current earnings power.
- Whale 13F Flow: 7 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is weak, indicating limited evidence of sustained institutional conviction in the source data.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The lowest pillar score here suggests insider activity in the source data does not provide a supportive signal.
- Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. This is the strongest pillar, but it reflects market-relative positioning rather than company-specific strength.
- Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 4.13, Piotroski F is 3/9, and Debt/Equity is 0.5. The Altman Z reading is comparatively supportive, while the Piotroski F-Score of 3/9 signals weak fundamental quality.
Valuation tradeoffs are difficult to assess because P/E, EPS, and EV/EBITDA are not available in source data. The absence of earnings multiples means a prospective investor cannot benchmark the price of $15.41 against profitability. Upside drivers, as far as the source data shows, depend on catalysts (see Recent Catalysts) rather than on current cash generation.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.9M | $-33.1M | $-9.0M | N/A | $-29.8M | $31.4M | N/A |
| FY 2024 | $0.6M | $-60.5M | $-57.8M | N/A | $-49.3M | $13.9M | N/A |
| FY 2023 | $0.0M | $-78.9M | $-74.6M | N/A | $-60.3M | N/A | N/A |
Per the SEC financials and market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Reported net loss narrowed from $-57.8M in FY 2024 to $-9.0M in FY 2025, while cash rose from $13.9M to $31.4M. Per the Roarable RQD rating, the Altman Z-Score is 4.13 and the Piotroski F-Score is 3/9. Debt/Equity is 0.5 per the Roarable RQD rating, though reported debt figures are N/A in the SEC financials.
Recent Catalysts & News Wire Analysis
Source headlines reference several items, all tagged to RLYB:
- A SEC Form 4 filing by Rallybio Corporation (catalyst tag).
- A CFO sale of 599 shares at $16.04 to cover vesting taxes (catalyst tag).
- A Business Wire investor alert stating that Kahn Swick & Foti, LLC is investigating the merger of Rallybio Corporation (catalyst tag).
- A TradingView headline attributing a 9M profit to a $50.0M termination fee as the Avenzo merger advanced (market wire tag, the only yellow-flagged item).
- A Form 4 filing by director Christine A. Nash dated 28 October (catalyst tag).
- A SEC filing dated Oct 16, 2026 (catalyst tag).
Risk watch items are the merger-related investigation notice and the termination-fee headline, which is flagged yellow. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.
Open Questions
- What are the company's products, pipeline, and revenue sources, given that the profile and financials do not describe them?
- What is the status and terms of the Avenzo merger, and what does the $50.0M termination fee mean for remaining shareholders?
- What are the debt levels, given that reported debt is N/A while Debt/Equity is cited at 0.5?
- What is the company's cash runway at the FY 2025 burn rate of $-29.8M in FCF, against $31.4M in cash?
- Why are EPS and valuation multiples absent, and what would a fair-value reference look like?
RLYB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Rallybio Corporation (RLYB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Quantisnow • 1h ago
SEC Form 4 filed by Rallybio Corporation Quantisnow report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stock Titan • 4h ago
To cover vesting taxes, Rallybio (RLYB) CFO sells 599 shares at $16.04. Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Business Wire • 7h ago
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB Business Wire report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 10h ago
RLYB: A $50.0M termination fee drove 9M profit as the Avenzo merger advanced TradingView report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com South Africa • 13h ago
Form 4 Rallybio Corp: Christine A. Nash (Director) For: 28 October By Investing.com Investing.com South Africa report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stock Titan • 16h ago
Rallybio Corp SEC Filing (Oct 16, 2026) Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 19h ago
Rallybio (RLYB) Edges Up 0.35% to $16.99, Sitting Midway Between Key Support and Resistance - Volume Profile https://www.siam.in/ report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stock Titan • 22h ago
A November 4 stockholder vote stands between Rallybio (RLYB) holders and a special cash payout. Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
RLYB Bull vs. Bear Conversation Board — What's Your Call at $15.54?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RLYB 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $13.56 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is RLYB (D- • RQD 37/100) a Buy at $15.41?
Welcome to the RLYB (Rallybio Corporation) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $12.02 (-22.0%)
Spot @ $15.41 Pump the brakes on RLYB — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on RLYB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Rallybio Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $18.49 (+20.0%)
Spot @ $15.41 RLYB cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on RLYB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.41 (52-wk range $13.41 - $16.80), any beat on forward guidance forces shorts and underweight funds to chase.